AHA 2019 ICYMI: Summaries of 11 late-breaking clinical trials presented at the 2019 Scientific Sessions held in Philadelphia, PA, Nov 16-18.
Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke
AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Progression of Subclinical Atherosclerosis Independently Predicts All-Cause Mortality
The use of visual imaging to detect atherosclerosis at its earliest stages and to quantify the burden enhances predictive value of traditional risk assessment tools.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
Statin Plus Ezetimibe Outperforms High-Dose Statins in LDL-C Reduction: Daily Dose
Your daily dose of the clinical news you may have missed.
Finerenone Improves Outcomes in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction
ESC 2024: Findings from the FINEARTS-HF clinical trial provide the first definite evidence that an MRA can be beneficial in patients with HFmrEF/HFpEF.